Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A bubbling chemical reaction in a glass beaker on a lab bench, surrounded by shelves of glassware.

May 15, 2026

Google-backed Isomorphic Labs Raises $ 2.1 Bn to Enhance AI-based Drug Discovery Platform

Isomorphic Labs, an AI-driven drug discovery company, has successfully raised $2.1 billion in a Series B funding round, primarily led by Thrive Capital and supported by Alphabet and Google’s GV. This significant investment aims to enhance its AI platform and therapeutic pipeline, further advancing its drug discovery capabilities.Founded by Demis Hassabis of Google DeepMind in 2021, Isomorphic Labs is leveraging predictive and generative AI models to innovate drug discovery processes. Central to
A minimalist illustration of a pill symbolizing drug discovery.

May 15, 2026

Google-Backed Isomorphic Labs Secures $2.1 Billion to Push AI Drug Discovery Forward

Isomorphic Labs, a London-based biotech firm backed by Google, has secured $2.1 billion in Series B funding to enhance its AI-driven drug discovery capabilities. This significant investment underscores the growing confidence in AI's potential to revolutionize pharmaceutical development, promising faster and more cost-effective drug design compared to traditional methods.Founded in 2021 by Demis Hassabis from Google DeepMind, Isomorphic Labs aims to leverage advanced AI technologies to transform
A minimalist illustration of a pill and capsule on a solid background.

May 15, 2026

Big Pharma Teams Up With AI Titans as the Race for “AI Bio” Innovation Intensifies

Big pharmaceutical companies are increasingly forming alliances with AI technology leaders to enhance drug development and regain competitive advantages in the market.Recent collaborations highlight this trend, with Novo Nordisk partnering with OpenAI to integrate artificial intelligence into various aspects of drug discovery, production, and supply chain management. This partnership aims to streamline processes and improve the efficiency of bringing new medications to market, particularly for o
AAV capsid and cell membrane illustration

May 14, 2026

Cell and Gene Therapy Catapult invests in Lir Therapeutics to accelerate development of its AI-driven AAV design platform

The Cell and Gene Therapy Catapult (CGT Catapult) is investing in Lir Therapeutics to enhance its AI-driven AAV capsid design platform, nAAVigator. This funding aims to facilitate biological validation and generate necessary data to attract pharmaceutical and biotech partnerships.Lir Therapeutics has developed a unique AI-based system that creates and selects novel adeno-associated virus (AAV) capsids, which are crucial for delivering gene therapies. These capsids transport therapeutic materials
A minimalist illustration of a nano-rocket and a drug capsule on a solid background.

May 13, 2026

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio, a Hong Kong-based startup, is revolutionizing drug delivery using AI technology, evidenced by a remarkable 173% surge in its stock price during its debut. This strong market response highlights the growing investor interest in AI-driven healthcare innovations.The company, which focuses on AI-enhanced drug design, priced its initial public offering at HK$10.50 per share, but it opened at HK$28.68, reflecting high demand. Co-founder and CEO Lai Tsai-Ta emphasized that their AI algor
Flat illustration of siRNA molecule and AI brain icon

May 12, 2026

Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI

Suzhou Ribo Life Science Co., Ltd. has forged a strategic partnership with Insilico Medicine to enhance the development of siRNA therapeutics using AI technologies.The collaboration focuses on integrating artificial intelligence into various stages of siRNA drug development, including target discovery and drug optimization. By combining Ribo's expertise in siRNA technology with Insilico's AI-driven drug discovery platform, the partnership aims to accelerate the creation of innovative therapies t
Minimalist illustration of a pluripotent stem cell and dopaminergic progenitor

May 12, 2026

AI to accelerate Novo Nordisk's Parkinson’s cell therapy

Novo Nordisk is partnering with Cellular Intelligence to enhance its Parkinson's cell therapy through AI technology, aiming to streamline development and commercialization processes.The collaboration allows Cellular Intelligence to leverage its AI foundation model to optimize Novo Nordisk's allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy, which is currently undergoing a Phase I/II clinical trial. This innovative approach is designed to significantly reduce the time requi
A small molecule drug compound on a lab bench with chemical reagents in the background.

May 11, 2026

AI cancer-therapy firm Lantern Pharma plans May 15 Q1 results

Lantern Pharma, a clinical-stage company specializing in AI-driven precision oncology, is set to release its Q1 2026 financial results on May 15, 2026. The upcoming report will cover the company's financial performance for the first quarter ending March 31, 2026, along with updates on its clinical trials and advancements in its AI technology. Lantern Pharma utilizes its proprietary AI and machine learning platform, RADR®, to enhance the drug discovery process for challenging cancers, including c
A petri dish with cell culture in a laboratory setting

May 11, 2026

Novo turns a Parkinson’s bet into a startup test

Novo Nordisk has transitioned its clinical-stage Parkinson's cell therapy, STEM-PD, to Cellular Intelligence, an AI-focused biotech supported by the Chan Zuckerberg Initiative. This strategic licensing deal illustrates a growing trend among pharmaceutical companies to offload non-core assets into specialized startups while maintaining a stake in their success through equity and potential royalties.By transferring STEM-PD, Novo Nordisk is not merely divesting a project but strategically managing
A glass flask with a colorful chemical compound in a dimly lit lab setting.

May 11, 2026

A year of advancing the Lilly-Purdue $250M research partnership to accelerate medicine discovery and manufacturing

The Lilly-Purdue partnership is making significant strides in pharmaceutical innovation and research, following its launch in May 2025.Since the announcement of a $250 million collaboration, Purdue University and Eli Lilly and Company have actively engaged in developing a shared research agenda aimed at enhancing drug discovery and manufacturing processes. This partnership, known as the Lilly-Purdue 360 Initiative, is notable for being the largest industry-academic agreement of its kind in the U
A stock certificate and financial report on a desk

May 8, 2026

Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares

Schrodinger Inc's recent financial performance has raised concerns among investors, as the company reported a larger-than-expected loss and fell short of revenue forecasts for Q1 2026, leading to a decline in its stock price.On May 7, 2026, Schrodinger's shares were trading at approximately $13.28 on Nasdaq. The company disclosed a net loss of around $60 million, or $0.81 per share, which is slightly worse than the previous year's loss of $59.8 million. This financial outcome has intensified scr
Minimalist illustration of an antibody and target

May 8, 2026

Europe's $154+ Million AI in Antibody Discovery Market,

The European market for AI in antibody discovery is poised for significant growth, projected to expand from approximately $153.8 million in 2025 to $1.43 billion by 2035, reflecting a compound annual growth rate (CAGR) of 25.05%.This growth is largely driven by the limitations of traditional antibody discovery methods, which are often costly and time-consuming. The integration of advanced technologies such as deep learning and generative AI is transforming the landscape, enabling more efficient